A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
Drivers' union ASLEF suspended industrial action scheduled for next week but the RMT Conductors' union strike remains in place.
Dozens of African-American former agents will receive $24 million in settlement of a class-action lawsuit alleging racial discrimination.
The case was triggered by wheelchair user Doug Paulley who boarded a bus but could not get on because a pram was in the wheelchair space.